Natera Acquires Foresight Diagnostics

Natera has completed its acquisition of Foresight Diagnostics for up to $450 million, consisting of $275 million upfront in stock and up to $175 million in revenue- and reimbursement-linked milestones. The deal brings Foresight’s ultrasensitive PhasED-Seq MRD and liquid-biopsy capabilities into Natera’s Signatera platform, strengthening Natera’s oncology and lymphoma diagnostics capabilities and accelerating clinical and biopharma partnerships.